{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:48:11Z","timestamp":1793400491056,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 20309"],"award-info":[{"award-number":["IG 20309"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001706","name":"Louis-Jeantet Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.molmed.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:19:24Z","timestamp":1677082764000},"page":"329-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Gene-based delivery of immune-activating cytokines for cancer treatment"],"prefix":"10.1016","volume":"29","author":[{"given":"Federico","family":"Rossari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Birocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Coltella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2023.01.006_bb0005","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The spectrum of benefit from checkpoint blockade in hypermutated tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0020","article-title":"Cytokine based immunotherapy for cancer and lymphoma: biology, challenges and future perspectives","volume":"2022","author":"Atallah-Yunes","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/pro.3668","article-title":"New toolsn in Escherichia coli: a 5-year update","volume":"28","author":"Rosano","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.molmed.2023.01.006_bb0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2023.01.006_bb0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm871","article-title":"Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells","volume":"9","author":"De Palma","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","article-title":"Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors","volume":"8","author":"De Palma","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2023.01.006_bb0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","article-title":"Tumor-targeted interferon-\u03b1 delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis","volume":"14","author":"De Palma","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2023.01.006_bb0055","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0060","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon\u2013dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006353","article-title":"Genetic engineering of hematopoiesis for targeted IFN-\u03b1 delivery inhibits breast cancer progression","volume":"6","author":"Escobar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0075","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28696","article-title":"Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-\u03b1 activates immunity and inhibits breast cancer progression","volume":"3","author":"Escobar","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.15252\/emmm.201505395","article-title":"IFN gene\/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment","volume":"8","author":"Catarinella","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0085","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1038\/s41467-018-05315-0","article-title":"Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens","volume":"9","author":"Escobar","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl4106","article-title":"Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models","volume":"14","author":"Birocchi","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/cancers13020230","article-title":"A set of cell lines derived from a genetic murine glioblastoma model recapitulates molecular and morphological characteristics of human tumors","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2023.01.006_bb0100","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013598","article-title":"Myeloid cell-based delivery of IFN-\u03b3 reprograms the leukemia microenvironment and induces anti-tumoral immune responses","volume":"13","author":"Mucci","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0105","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jnci\/djz181","article-title":"Hematopoietic stem cell gene therapy for brain metastases using myeloid cell-specific gene promoters","volume":"112","author":"Andreou","year":"2020","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2023.01.006_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001143","article-title":"Hematopoietic stem cell gene therapy targeting TGF\u03b2 enhances the efficacy of irradiation therapy in a preclinical glioblastoma model","volume":"9","author":"Andreou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067567","article-title":"Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-\u03b2 against peritoneally disseminated cancer in xenograft models","volume":"8","author":"Koba","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2023.01.006_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2326-6066.CIR-15-0096","article-title":"Immunotherapy against metastatic melanoma with human iPS cell-derived myeloid cell lines producing type I interferons","volume":"4","author":"Miyashita","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0125","first-page":"7853","article-title":"Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model","volume":"63","author":"Satoh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0135","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2023.01.006_bb0140","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","article-title":"Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice","volume":"31","author":"Parente-Pereira","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0145","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/gt.2015.43","article-title":"Lentivirus-induced \u2018Smart\u2019 dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma","volume":"22","author":"Sundarasetty","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0160","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/eji.201545559","article-title":"The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome","volume":"45","author":"Goyvaerts","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0165","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/onci.20504","article-title":"AAV2\/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications","volume":"1","author":"You","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0170","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0175","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2023.01.006_bb0180","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2023.01.006_bb0185","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2023.01.006_bb0190","first-page":"2983","article-title":"Gene-edited interleukin CAR-T cells therapy in the treatment of malignancies: present and future","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2023.01.006_bb0200","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.006_bb0205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/mthe.2000.0050","article-title":"IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector","volume":"1","author":"Mizuguchi","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nbt1049","article-title":"Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters","volume":"23","author":"Amendola","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0215","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"4","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0220","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.ymthe.2021.05.006","article-title":"Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models","volume":"29","author":"Webster","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0225","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/acssynbio.1c00236","article-title":"Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activation","volume":"11","author":"Guo","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0230","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.006_bb0235","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.006_bb0240","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0245","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0250","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.molmed.2023.01.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003486","article-title":"Time to evolve: predicting engineered T cell-associated toxicity with next-generation models","volume":"10","author":"Donnadieu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0260","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1016\/j.jtho.2016.11.405","article-title":"MA04.11 mechanistic insights into CAR T-cell efficacy in the treatment of heterogenous antigen expressing lung adenocarcinoma","volume":"12","author":"Morello","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"O\u2019Cearbhaill","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0270","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2023.01.006_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-01664-7","article-title":"Synthetic promoters to induce immune-effectors into the tumor microenvironment","volume":"4","author":"Greenshpan","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100227","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Reports Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0285","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.006_bb0290","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2023.01.006_bb0295","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0300","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-10-7230-7_4","article-title":"Oncolytic virotherapy by HSV","volume":"1045","author":"Watanabe","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0305","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0310","first-page":"4434","article-title":"E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer","volume":"63","author":"Fukuda","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0315","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers12061504","article-title":"Oncolytic adenoviruses: strategies for improved targeting and specificity","volume":"12","author":"Hajeri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2023.01.006_bb0320","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.molmed.2023.01.006_bb0325","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1873-3468.13731","article-title":"Retargeting adenoviruses for therapeutic applications and vaccines","volume":"594","author":"Barry","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2023.01.006_bb0330","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0335","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: first in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.molmed.2023.01.006_bb0340","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0345","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0350","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/mthe.2000.0130","article-title":"Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte\u2013macrophage colony-stimulating factor","volume":"2","author":"Toda","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0355","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0360","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2023.01.006_bb0365","first-page":"3268","article-title":"Clinical activity of single dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.molmed.2023.01.006_bb0370","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-\u03b1 has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.molmed.2023.01.006_bb0375","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.006_bb0380","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.006_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2023.01.006_bb0395","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0400","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.molmed.2023.01.006_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2022-0002","article-title":"Cancer gene therapy goes viral: viral vector platforms come of age","volume":"56","author":"Bezeljak","year":"2022","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0410","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00705-022-05432-8","article-title":"Viruses as tools in gene therapy, vaccine development, and cancer treatment","volume":"167","author":"Bin Umair","year":"2022","journal-title":"Arch. Virol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0415","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1016\/j.vaccine.2010.03.041","article-title":"Advances in viral-vector systemic cytokine gene therapy against cancer","volume":"28","author":"Liu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2023.01.006_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0425","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0435","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0440","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic Notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.molmed.2023.01.006_bb0445","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.molmed.2023.01.006_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1890","article-title":"Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics","volume":"8","author":"Cripe","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2023.01.006_bb0455","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1093\/neuonc\/noac174.042","article-title":"OS05.6.A modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109)","volume":"24","author":"Finocchiaro","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0460","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2023.01.006_bb0465","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2023.01.006_bb0470","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","article-title":"Human IL-2 mutein with higher antitumor efficacy than wild type IL-2","volume":"190","author":"Carmenate","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0475","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41598-018-37280-5","article-title":"Directed evolution of super-secreted variants from phage-displayed human interleukin-2","volume":"9","author":"Rojas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.006_bb0480","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.006_bb0485","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0495","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.006_bb0500","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0505","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2023.01.006_bb0510","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0515","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0520","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1073\/pnas.83.10.3194","article-title":"Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells","volume":"83","author":"Yu","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2023.01.006_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.molmed.2023.01.006_bb0530","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/asheducation-2009.1.682","article-title":"Ten years of gene therapy for primary immune deficiencies","volume":"2009","author":"Aiuti","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0535","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2023.01.006_bb0540","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1089\/hum.2021.142","article-title":"Investigating the barrier activity of novel, human enhancer-blocking chromatin insulators for hematopoietic stem cell gene therapy","volume":"32","author":"Papayanni","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2023.01.006_bb0545","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0550","first-page":"1","article-title":"Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2023.01.006_bb0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.molmed.2023.01.006_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","author":"Bell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2023.01.006_bb0565","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2023.01.006_bb0570","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.molmed.2023.01.006_bb0575","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molmed.2023.01.006_bb0580","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491423000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:52:13Z","timestamp":1778615533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491423000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1471491423000308"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2023.01.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene-based delivery of immune-activating cytokines for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}